Observational studyMedicine2025
Carotid femoral pulse wave velocity and serum galectin-3 level significantly increases in patients with acromegaly.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin-like growth factor-1 (IGF-1) and growth hormone release is elevated in acromegaly, a chronic condition. Our objective was to study the correlation between carotid femoral pulse wave velocity (CF-PWV) and galectin-3 level in acromegaly patients. This protein is believed to alter in response to early inflammation and atherosclerosis. Our study was planned as a prospective, single-center cross-sectional study. Our study comprised 40 healthy controls and 40 newly diagnosed acromegaly patients ranging in age from 18 to 65 years old at Adana City Training and Research Hospital. The patients' IGF-1, growth hormone, hemogram, and biochemistry values were assessed. Human galectin-3 kits and the Enzyme-Linked Immunosorbent Assay were used to measure the amount of galectin-3. Patients underwent CF-PWV assessments with the use of Doppler ultrasonography and concurrent electrocardiography. Our investigation indicated that acromegaly patients had greater levels of the fibrosis and inflammation indicator galectin-3 as well as the gold standard indication of arterial stiffness, CF-PWV. We observed a link between blood galectin-3 level and both IGF-1 level and CF-PWV measures in the correlation analysis. Galectin-3 has the potential to be a novel biomarker for the diagnosis and prognosis of cardiovascular disease in acromegaly patients, as well as a therapeutic target for the development of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.